Skye Bioscience CapEx/OCF

What does Skye Bioscience do? Skye Bioscience Inc generates revenue through the development and commercialization of cannabinoid derivatives targeting the endocannabinoid system. The company focuses on products like SBI-100 OE for glaucoma and ocular hypertension, and SBI-200 for conditions including uveitis, dry eye syndrome, macular degeneration, and diabetic eye diseases. Clinical trials for SBI-100 OE are underway in Australia with healthy volunteers to assess safety and efficacy. SBI-200 is being developed in various formulations to address analgesic, anti-inflammatory, anti-fibrotic, and anti-seizure needs. The primary buyers of Skye Bioscience's products are pharmaceutical companies seeking to expand their therapeutic portfolios. These companies purchase cannabinoid-based treatments for ophthalmic disorders and other unmet medical needs. The company's lead product SBI-100 OE is in Phase I trials, while SBI-200 targets multiple disease areas including eye-related conditions and neurological disorders. Skye Bioscience's business model centers on advancing clinical-stage drug candidates to market readiness. Skye Bioscience operates within the biopharmaceutical sector, developing innovative cannabinoid derivatives without direct consumer sales. The company's revenue streams are derived from potential future partnerships, licensing agreements, and eventual product sales once clinical trials succeed. The focus remains on advancing SBI-100 OE and SBI-200 through clinical development to secure commercialization opportunities. Skye Bioscience is one of the most popular companies on Eulerpool.